Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multiple Sclerosis (MS) Clear all
Completed No phase listed Observational Accepts healthy volunteers

Correlation Between Relapses in Multiple Sclerosis (MS) and Vitamin D Intake

NCT01994018
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Jul 23, 2026, 4:34 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis

NCT00654927
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR b.i.d. (Twice Daily)
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2012 · Synced Jul 23, 2026, 4:34 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

HFS (High-Fiber Supplement) in MS (Multiple Sclerosis)

NCT04574024
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
NBT-NM108
Drug
Lead sponsor
Suhayl Dhib-Jalbut, MD
Other
Eligibility
21 Years to 55 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Jul 23, 2026, 4:34 AM EDT
Recruiting Not applicable Interventional

Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis

NCT05051618
View directory record Official record
Conditions
Multiple Sclerosis, Major Depressive Disorder
Interventions
POWER-MS, FLEX-MS
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 64 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 23, 2026, 4:34 AM EDT
Completed No phase listed Observational

Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.

NCT01031459
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Betaseron (Interferon beta-1b, BAY86-5046)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2012 · Synced Jul 23, 2026, 4:34 AM EDT
Completed Phase 4 Interventional Results available

The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial

NCT01034579
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Blood sampling
Other
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2014 · Synced Jul 23, 2026, 4:34 AM EDT
Completed No phase listed Observational

The Gilenya Pregnancy Registry

NCT01285479
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fingolimod
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Female only
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Cambridge, Massachusetts • Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Jul 23, 2026, 4:34 AM EDT
Withdrawn No phase listed Observational

VALIDATE: Factor VIII Trending for MS Relapse

NCT04082468
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Blood sample collection for coagulation profile
Diagnostic Test
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Jul 23, 2026, 4:34 AM EDT
Completed Phase 3 Interventional Results available

Escitalopram (Lexapro) for Depression MS or ALS

NCT00965497
View directory record Official record
Conditions
Major Depression, Multiple Sclerosis, Amyotrophic Lateral Sclerosis
Interventions
escitalopram
Drug
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Jul 23, 2026, 4:34 AM EDT
Suspended No phase listed Observational

Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis

NCT05949580
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
MS Care Platform (icobrain ms and icompanion ms)
Device
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Golden Valley, Minnesota • Hackensack, New Jersey • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 4:34 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

NCT04926818
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Fingolimod, Ofatumumab, Siponimod, Fingolimod placebo, Siponimod placebo, Ofatumumab placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 23, 2026, 4:34 AM EDT
Completed Phase 4 Interventional

An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS

NCT00206648
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Betaferon/Betaseron
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
51
States / cities
Tucson, Arizona • Berkeley, California • Irvine, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Jul 23, 2026, 4:34 AM EDT
Completed Not applicable Interventional

Emotion Regulation Skills Training for Individuals With MS and Their Support Partners

NCT03934489
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
PERSIST, Facilitated Peer Support
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Jul 23, 2026, 4:34 AM EDT
Completed Not applicable Interventional

Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya

NCT02141022
View directory record Official record
Conditions
Multiple Sclerosis, Cognitive Deficits, Gilenya Modifying Therapy for MS
Interventions
plasticity-based computerized cognitive remediation program, Gileyna
Other · Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Jul 23, 2026, 4:34 AM EDT
Terminated Phase 3 Interventional Results available

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

NCT01058005
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
BG00002 (natalizumab), interferon beta-1a, glatiramer acetate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2014 · Synced Jul 23, 2026, 4:34 AM EDT
Completed Phase 4 Interventional

NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness

NCT01591551
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab (Tysabri)
Drug
Lead sponsor
Cornerstone Health Care, PA
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Patchogue, New York • High Point, North Carolina • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Jul 23, 2026, 4:34 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GTR in Comparison to Copaxone®

NCT01489254
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®), Placebo
Drug
Lead sponsor
Synthon BV
Industry
Eligibility
18 Years to 55 Years
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
Irvine, California • Port Charlotte, Florida • Sunrise, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Jul 23, 2026, 4:34 AM EDT
Terminated Phase 1 Interventional

Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS

NCT00638196
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Linoleic Acid/Oleic Acid
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Jul 23, 2026, 4:34 AM EDT
Not yet recruiting Phase 3 Interventional

Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project

NCT07472413
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cetirizine, Diphenhydramine
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 23, 2026, 4:34 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS

NCT02797015
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
RPC1063
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Long Beach, California • San Francisco, California • Raleigh, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Jul 23, 2026, 4:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Monitoring of Multiple Sclerosis (MS) Participants With the Use of Digital Technology (Smartphones and Smartwatches) - A Feasibility Study

NCT02952911
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Smartphone and Smartwatch
Device
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Jul 23, 2026, 4:34 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

NCT05147220
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Remibrutinib, Teriflunomide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
52
States / cities
Phoenix, Arizona • Tucson, Arizona • Fort Smith, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 23, 2026, 4:34 AM EDT
Recruiting Phase 2 Interventional

Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

NCT07497399
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
NLY01, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 4:34 AM EDT
Completed Not applicable Interventional

Mobile Attentional Bias Modification Training in Pediatric MS

NCT04441229
View directory record Official record
Conditions
Pediatric Multiple Sclerosis
Interventions
ABMT mobile application
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
12 Years to 24 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Jul 23, 2026, 4:34 AM EDT